OncoMatch/Clinical Trials/NCT06932744

Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

Is NCT06932744 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including MY008211A tablets and Eculizumab for paroxysmal nocturnal haemoglobinuria (pnh).

Phase 3RecruitingWuhan Createrna Science and Technology Co., LtdNCT06932744Data as of May 2026

Treatment: MY008211A tablets · Eculizumab — The main purpose of this study is to evaluate the efficacy of MY008211A compared to eculizumab in PNH patients.

Check if I qualify

Extracted eligibility criteria

Prior therapy

No prior treatment (treatment-naive required)

Cannot have received: bone marrow or hematopoietic stem cell transplantation

Previous bone marrow or hematopoietic stem cell transplantation

Cannot have received: splenectomy

Previous splenectomy

Lab requirements

Blood counts

reticulocytes ≥ 100x10^9/L; platelets ≥ 30x10^9/L; neutrophils ≥ 0.5x10^9/L

Patients with reticulocytes <100x10^9/L; platelets <30x10^9/L; neutrophils <0.5x10^9/L [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify